Europese Unie - Italiaans - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. tranne che nel recente diagnosi di lmc in fase cronica, non ci sono studi clinici controllati che dimostrano un beneficio clinico o un aumento della sopravvivenza per queste malattie. .

Zwitserland - Italiaans - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - methotrexatum - compresse - methotrexatum 2.5 mg ut methotrexatum natricum, lactosum monohydricum 66.166 mg, amylum pregelificatum, magnesii stearas, natrii hydroxidum, pro compresso corresp. natrium 0.268 mg. - farmaco - synthetika

Zwitserland - Italiaans - Swissmedic (Swiss Agency for Therapeutic Products)

orion pharma ag - methotrexatum - compresse - methotrexatum 2.5 mg ut methotrexatum natricum corresp. natrium 0.229 mg, lactosum monohydricum 81.9 mg, cellulosum microcristallinum, magnesii stearas pro compresso. - trattamento di malattie autoimmuni come l'artrite reumatoide / trattamento di gravi casi incontrollabile psoriasi nei confronti convenzionali di terapia topica - synthetika

Zwitserland - Italiaans - Swissmedic (Swiss Agency for Therapeutic Products)

orion pharma ag - methotrexatum - compresse - methotrexatum 10 mg ut methotrexatum natricum corresp. natrium 0.918 mg, lactosum monohydricum 327.6 mg, cellulosum microcristallinum, magnesii stearas pro compresso. - trattamento di malattie autoimmuni come l'artrite reumatoide / trattamento di gravi casi incontrollabile psoriasi nei confronti convenzionali di terapia topica - synthetika

Italië - Italiaans - AIFA (Agenzia Italiana del Farmaco)

dr. reddy's s.r.l. - imatinib - imatinib

Zwitserland - Italiaans - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - daunorubicini hydrochloridum - polvere per concentrato per soluzione per infusione - daunorubicini hydrochloridum 20 mg, mannitolum, pro vitro. - remissionsinduktion bei akuten lymphoblastischen bzw. lymphatischen (all) und bei akuten myeloischen leukämien (aml). - synthetika

Italië - Italiaans - Ministero della Salute

desa pharma srl -

Italië - Italiaans - Ministero della Salute

du pont de nemours italiana s.r.l. - metribuzin sono; - granulare idrodispersibile - 35.0 g i valori indicati sono per 100 g di prodotto. - diserbante - diserbante - (xn) nocivo

Italië - Italiaans - Ministero della Salute

arysta lifescience benelux sprl - metribuzin sono; - granulare idrodispersibile - 70.0 g i valori indicati sono per 100 g di prodotto. - diserbante - diserbante - (xn) nocivo

Italië - Italiaans - Ministero della Salute

arysta lifescience benelux sprl - metribuzin sono; - granulare idrodispersibile - 35.0 g i valori indicati sono per 100 g di prodotto. - diserbante